Pablo Ruiz-Ramon, MD
Nephrology · Temple Terrace, FLNPI 1598728537
Payments from drug & device makers
Across 319 payments — averaging $3798.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$713K
- AstraZeneca$254K
- Vertex$132K
- Travere Therapeutics, Inc.$56K
- Bayer$23K
- Boehringer Ingelheim$17K
- plus $16K from 26 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 15 | $713,231 |
| AstraZeneca(2 entities) | 50 | $254,208 |
| Vertex | 7 | $131,672 |
| Travere Therapeutics, Inc. | 49 | $56,434 |
| Bayer | 30 | $23,316 |
| Boehringer Ingelheim | 5 | $17,051 |
| Boehringer Ingelheim International GmbH | 3 | $9,680 |
| Novartis | 7 | $1,789 |
| Otsuka America Pharmaceutical, Inc. | 26 | $1,011 |
| Amgen(2 entities) | 25 | $599 |
| Aurinia Pharma U.S., Inc. | 11 | $471 |
| Calliditas Therapeutics US Inc. | 10 | $219 |
| Fresenius USA Marketing, Inc. | 10 | $217 |
| Akebia Therapeutics Inc | 12 | $211 |
| OPKO Pharmaceuticals, LLC | 11 | $202 |
| Mallinckrodt Hospital Products Inc. | 8 | $189 |
| Daiichi Sankyo Inc. | 9 | $189 |
| Mallinckrodt Enterprises LLC | 5 | $163 |
| Ardelyx, Inc. | 2 | $143 |
| Foundation Fusion Solutions, LLC | 1 | $129 |
| ANI Pharmaceuticals, Inc. | 4 | $111 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $111 |
| Novo Nordisk | 3 | $64 |
| Veloxis Pharmaceuticals, Inc. | 1 | $54 |
| Alnylam Pharmaceuticals Inc. | 3 | $48 |
| Vifor Pharma, Inc. | 3 | $47 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $32 |
| Arbor Pharmaceuticals, Inc. | 2 | $29 |
| Bard Peripheral Vascular, Inc. | 1 | $24 |
| Lilly USA, LLC | 1 | $23 |
| Cormedix Inc. | 1 | $16 |
| Shire North American Group Inc | 1 | $13 |
How this compares
$1,211,695 in reported general payments places this provider in the 95th percentile of 756 nephrology providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other nephrology in Temple Terrace
- Amit JohnsinghTemple Terrace$1.5M
- Jason RothschildTemple Terrace$413K
- Thomas MarburyOrlando$41.1M
- Julio VijilHollywood$16.1M
- Steven ZeigHollywood$14.3M
- Oscar GalvezMiami$14.2M
- Jesus NavarroTampa$13.3M
- Arvind MadanOrlando$9.7M
- David HalpertAtlantis$4.2M
- Wayne KotzkerFort Lauderdale$3.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.